Harvesting soybeans will be less profitable in 2016 than in recent years. Ditto for corn. Image source: United Soybean Board / Flickr.

Last month I met Tag, a seasoned soybean farmer from the Midwest, who admitted that he was feeling the commodities squeeze that's pushing corn and soy prices to five-year lows. Worse yet, while he loved using Monsanto (NYSE:MON) products, he was frustrated that the company hadn't lowered prices enough to help farmers through the current market.

Consider that perspective when digesting Wall Street's opinion over the past year that the sky is falling for the industry (Hint: It's not) and encouraging consolidation to insulate income statements from short-term pressures.

Investors are right to sit up in their chairs, however. The commodities trend is forcing farmers to cut back on fertilizers, next-generation seeds, and crop protection technologies, which, in turn, has pushed agricultural technology companies to lower prices -- not enough for some farmers, and too far for some investors. That resulted in double-digit declines in many important financial categories for Monsanto in the quarterly year-over-year comparisons. Let's put the recent quarter into context of significant short-term and, importantly, long-term factors.

By the numbers
It may be a little confusing that the company reports certain financial metrics in two ways: "ongoing" and "as-reported." The definition for the former gets a little messy, but it's essentially a way for Monsanto to (1) exclude operations that are no longer current and (2) calculate currency-neutral values by adjusting for varying currency exchange and tax rates in the various regions where it operates. Why? Currency headwinds have become increasingly fierce in the last several years. No matter: The following table considers only "as-reported" values, which are not adjusted.


Q2 2015

Q2 2016

% Change

Revenue, Seeds and Genomics

$4,178 million

$3,817 million


Revenue, Agricultural Productivity

$1,019 million

$715 million


Total Revenue

$5,197 million

$4,532 million


Total Gross Profit

$3,039 million

$2,598 million


Diluted EPS




Data source: Monsanto Q2 2016 press release.

As a brief refresher on Monsanto's segments, Seeds and Genomics includes biotechnology platforms, genetic traits, and the digital agriculture platform, while Agricultural Productivity includes crop-protection products and consumer lawn-care herbicides. The former accounts for the lion's share of the revenue and profits.

Just about every subcategory contributed to the quarterly year-over-year declines. Glyphosate sales were down, corn and soybeans were discounted in the United States, and soybean volumes were reduced thanks to lower acres this season. That was partially offset by reduced operating expenses, an uptick in Brazil corn pricing, and increased adoption of the company's Intacta RR2 PRO soybean platform.

Financial guidance
Monsanto maintained guidance for ongoing EPS in the range of $4.40 to $5.10 per share. Of course, investors will remember that the company lowered expectations in early March from a previously reported range of $5.10 to $5.60 per share last December. That would represent the lowest full-year EPS for the company since the 2012 or 2013 fiscal year, depending on where it falls within the range.

Image source: Monsanto 2Q16 presentation.

Knowing that, it may not be a surprise that shares are trading at the lowest level since the company's 2012 fiscal year ended August 2012. So, while I'm not usually a fan of share repurchase programs -- because companies and investors are terrible at timing the market -- Monsanto's current $3 billion effort is intriguing. There's no guarantee that shares won't head lower from here (already 30% of highs set in early 2015), but the company's restructuring efforts are expected to save over $500 million in operating expenses per year when completed. More important, there are several impressive product portfolios in the early stages of commercialization that support the long-term view.

Long-term outlook
It may be difficult to tell from the year-over-year financial comparison, but Monsanto did pile up quite a few wins in the second quarter -- they were just small in magnitude. The roll-out of Intacta RR2 PRO underscores one of Monsanto's biggest core strengths: its industry-leading R&D pipeline. The portfolio is expected to soar to 35 million acres this year, only it's third, from 15 million acres in 2015.

Throw in several other fast-growing platforms in the infant stages of commercialization, and the long-term outlook becomes quite a bit more impressive.


2016 Target

Long-Term Target

Intacta RR2 PRO Soybeans

35 million acres

100 million acres (75 million acres by 2019)

Roundup Ready 2 Xtend Soybean

3 million acres (U.S.)

>53 million acres by 2019 (U.S.)

Bollgard II XtendFlex Cotton

>2 million acres (U.S.)

>5 million acres

Climate Platform / Digital Agriculture

12 million acres of paying customers

>300 million acres of paying customers by 2025

Nemastrike Technology

R&D: Phase 4

125 million acres by 2025

Roundup Ready Xtend Corn

R&D: Phase 4

75 million acres

BioAg Alliance (Microbials)

R&D: Phase 1

250 million-500 million acres by 2025

Data source: Compiled by author from Monsanto 2Q16 presentation.

This strong pipeline is key to Monsanto's announcement that it will abandon megamerger opportunities that have distracted management and investors in the past year. Instead, it sees its best opportunities in smaller acquisitions -- not surprisingly the source of several blockbuster-hopeful products and platforms in the preceding list. I think investors should be overjoyed with the decision to double down on the R&D pipeline.

What does it mean for investors?
I can't provide insight into when the commodities squeeze will reverse course and bail out farmers and Monsanto alike. (Sorry, Tag.) However, there's a strong incentive for agricultural technology companies to double down on growth, exercise financial discipline, and provide great products and services to customers. The latter could result in further price reductions in the coming quarters, but Monsanto seems poised for continued long-term growth, regardless of harvest-to-harvest pricing concerns. Even a weak second quarter hinted at that trend; investors just have to know what to watch.